 |
인쇄하기
취소
|
AstraZeneca and Takeda Chemical promote Atacan's landmark clinical trials
AstraZeneca announced on March 4 that the large-scale DIabetic REtinopathy Candesartan Trials (DIRECT) was completed in February.
The DIRECT Programme, conducted and jointly sponsored by AstraZeneca and Takeda Chemical Ind., is the first Programme designed to establish whether treatment with an angiotensin II type 1 (AT1) receptor blocker, candesartan cilexetil, targeting the renin angiotens...
The DIRECT Programme, conducted and jointly sponsored by AstraZeneca and Takeda Chemical Ind., is the first Programme designed to establish whether treatment with an angiotensin II type 1 (AT1) receptor blocker, candesartan cilexetil, targeting the renin angiotens...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.